In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive industry comparison, evaluating CME Gr (NASDAQ:CME) against its key competitors in the Capital Markets industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.

Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The CME was founded in 1898 and in 2002 completed its initial public offering. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival, CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX in 2018 it has also expanded into cash foreign exchange, fixed income trading, and collateral optimization.

• With a Price to Earnings ratio of 25.42, which is 0.58x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.

• Considering a Price to Book ratio of 2.72, which is well below the industry average by 0.51x, the stock may be undervalued based on its book value compared to its peers.

• The stock's relatively high Price to Sales ratio of 14.32, surpassing the industry average by 1.82x, may indicate an aspect of overvaluation in terms of sales performance.

• With a Return on Equity (ROE) of 2.65% that is 1.19% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.

• With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.1 Billion, which is 2.97x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.

• Compared to its industry, the company has higher gross profit of $1.13 Billion, which indicates 2.17x above the industry average, indicating stronger profitability and higher earnings from its core operations.

• The company's revenue growth of 8.96% is notably higher compared to the industry average of -0.67%, showcasing exceptional sales performance and strong demand for its products or services.

The PE, PB, and PS ratios for CME Gr indicate that the company is undervalued compared to its peers in the Capital Markets industry. The low PE and PB ratios suggest that the stock is trading at a lower price relative to its earnings and book value. However, the high PS ratio indicates that the stock is trading at a higher price relative to its sales. In terms of profitability, CME Gr has a low ROE, but high EBITDA and gross profit margins. Additionally, the company has shown strong revenue growth compared to its industry peers.